Overview

This trial is active, not recruiting.

Conditions adult primary liver cancer, hepatitis c infection
Treatments s-adenosyl-l-methionine disulfate p-toluene-sulfonate, placebo, laboratory biomarker analysis, immunoenzyme technique, high performance liquid chromatography
Phase phase 2
Sponsor National Cancer Institute (NCI)
Start date October 2007
End date August 2012
Trial size 110 participants
Trial identifier NCT00513461, CDR0000558657, N01CN35160, NCI-2009-00897, UCI 06-07

Summary

This randomized phase II trial studies how well S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) works compared to a placebo in preventing liver cancer in patients with chronic hepatitis C infection. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of SAMe may keep cancer from forming in patients with advanced liver disease

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator)
Primary purpose prevention
Arm
(Experimental)
Patients receive SAMe PO BID for 24 weeks in the absence of disease progression or unacceptable toxicity.
s-adenosyl-l-methionine disulfate p-toluene-sulfonate SAMe disulfate p-toluene-sulfonate
Given PO
laboratory biomarker analysis
Correlative studies
immunoenzyme technique immunoenzyme techniques
Correlative studies
high performance liquid chromatography HPLC
Correlative studies
(Placebo Comparator)
Patients receive placebo PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
placebo PLCB
Given PO
laboratory biomarker analysis
Correlative studies
immunoenzyme technique immunoenzyme techniques
Correlative studies
high performance liquid chromatography HPLC
Correlative studies

Primary Outcomes

Measure
Change in serum AFP levels
time frame: Baseline to week 24

Secondary Outcomes

Measure
Treatment-related changes in additional serum markers for hepatocellular carcinoma
time frame: Baseline to week 24
Change in markers of liver disease
time frame: Baseline to week 24
Changes in markers of oxidative stress
time frame: Baseline (week 0) to week 24
Change in SAMe metabolites
time frame: Baseline to week 24
Safety and tolerability of SAMe
time frame: Up to week 24
Changes in quality of life
time frame: Baseline to week 24

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Chronic hepatitis C infection diagnosed by presence of hepatitis C ribonucleic acid (RNA) in serum by test of hepatitis C virus (HCV) RNA - No significant alcohol use (7 or fewer drinks per week) for the past 12 months - Serum AFP (at screening) between 15 and 100 ng/mL (15 ng/mL =< AFP =< 100 ng/mL) as measured by the Bayer Advai Centaur chemiluminescence system OR Serum AFP between 10 and 100 ng/mL (10 ng/mL =< AFP =<100 ng/mL) as measured by Diagnostic Products Corporation Immulite assay system OR AFP between 12 and 100 ng/mL (12 ng/mL =< AFP =< 100 ng/mL) as measured by Ortho ECiQ assay system - Evidence of advanced liver disease based on one or more of the following: - Platelet count less than 150,000/mm^3 - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio > 0.75 - Liver biopsy demonstrating bridging fibrosis or cirrhosis - No treatment with interferon (recombinant interferon alfa), peginterferon (PEG-interferon alfa-2b), or ribavirin for at least 4 months, and not anticipated to start specific treatment for hepatitis C during the study (30 weeks) - Ultrasound (or adequate computed tomography [CT] or magnetic resonance imaging [MRI]) examination of the liver within 6 months prior to randomization revealing no masses in the liver suggestive of hepatocellular carcinoma - Willing to refrain from consuming over-the-counter SAMe and vitamin pills containing B-vitamins while participating in this study (30 weeks) - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 - Leukocytes > 1,000/ mm^3 - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately - Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: - Liver disease other than from hepatitis C (e.g., hepatitis B, hemochromatosis, fat in more than 33% of hepatocytes, if liver biopsy has been performed., etc.); subjects with a past history of alcohol use can be enrolled into the study provided they have consumed less than 7 drinks/week for the past 12 months - Evidence of mass in liver by radiologic examination that is suggestive of hepatocellular carcinoma within 6 months prior to randomization - Model for End-Stage Liver Disease (MELD) score greater than 15 within 60 days prior to enrollment - Ascites which is clinically detectable - Use of SAMe during 4 months prior to randomization - Hospitalization within the past 5 years for mania or for bipolar disease - Concurrent use of monoamine oxidase inhibitors (MAO) or other drugs that increase the concentration of serotonin - Participants may not be receiving any other investigational agents - History of allergic reactions attributed to compounds of similar chemical or biologic composition to SAMe - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Children are excluded from this study but will be eligible for future pediatric trials, if applicable - Pregnant women are excluded from this study; serum pregnancy must be performed and be negative in all women of child bearing potential within 2 weeks prior to enrollment; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with SAMe, breastfeeding should be discontinued if the mother is treated with SAMe - Subjects with any medical psychosocial condition that, in the opinion of the investigator, could jeopardize the subject's participation in and compliance with the study criteria

Additional Information

Official title A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Principal investigator John Hoefs
Description PRIMARY OBJECTIVE: I. To determine whether treatment with SAMe for 24 weeks reduces serum level of alpha-fetoprotein (AFP) in patients with advanced liver disease due to chronic hepatitis C. SECONDARY OBJECTIVE: I. To determine whether treatment with SAMe for 24 weeks reduces serum levels of des-gamma carboxyprothrombin (DCP) and alpha-fetoprotein-L3 (AFP-L3) in patients with advanced liver disease due to chronic hepatitis C (hepatocellular carcinoma tumor markers). II. To determine whether treatment with SAMe for 24 weeks alters biochemical markers of liver disease (e.g., serum alanine aminotransferase [ALT], aspartate aminotransferase [AST], albumin, or bilirubin, etc.) and hepatitis C viral load in patients with advanced liver disease due to chronic hepatitis C (hepatitis C liver disease). III. To determine whether treatment with SAMe for 24 weeks reduces serum levels of tumor necrosis factor-alpha (TNF-alpha), plasma levels of malondialdehyde (MDA), 4-hydroxynonenal (4-HNE) and urine levels of F2-isoprostane in patients with advanced liver disease due to chronic hepatitis C (oxidative stress). IV. To determine whether treatment with SAMe for 24 weeks reduces plasma levels of methionine and homocysteine and increases plasma glutathione (GSH) and SAMe in patients with advanced liver disease due to chronic hepatitis C (SAMe metabolites). V. To determine the safety, tolerability and quality of life of SAMe treatment (up to 2,400 mg/day) for 24 weeks in patients with advanced liver disease due to chronic hepatitis C. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive SAMe orally (PO) twice daily (BID) for 24 weeks in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive placebo PO once daily (QD) for weeks 1-4, PO BID for weeks 5-8, and PO three times daily (TID) for weeks 9-24 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 6 weeks.
Trial information was received from ClinicalTrials.gov and was last updated in February 2013.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).